OPC-21268 hydrate

• 产品号: O1016
• CAS号: 131631-89-5(anhydrous)
• 分子式: C26H33N3O5
• 分子量: 467.55732
• 纯 度: ≥98% (HPLC)

产品别名

• 标题: OPC-21268 hydrate
• IUPAC标准名: N-(3-{4-[4-(2-oxo-1,2,3,4-tetrahydroquinolin-1-yl)piperidine-1-carbonyl]phenoxy}propyl)acetamide hydrate
• IUPAC传统名: N-(3-{4-[4-(2-oxo-3,4-dihydroquinolin-1-yl)piperidine-1-carbonyl]phenoxy}propyl)acetamide hydrate
• 别名: N-[3-[4-[[4-(3,4-dihydro-2-oxo-1(2H)-quinolinyl)-1-piperidinyl]carbonyl]phenoxy]propyl]-acetamide hydrate; 1-{1-[4(3-acetylaminopropoxy)benzoyl]-4-piperidyl}-3,4-dihydro-2(1H)-quinolinone hydrate

产品登记号

• MDL号: MFCD18632552
• CAS号: 131631-89-5(anhydrous)

产品性质

• Empirical Formula (Hill Notation): C26H31N3O4 · xH2O
• 纯度: ≥98% (HPLC)
• 外观: white to off-white powder
• 溶解度: DMSO: ≥20 mg/mL
• GHS警示词: Warning
• GHS危险声明: H302-H400
• 欧盟危险性物质标志: 有害性(Harmful) (Xn)
• 欧盟危险性物质标志: 环境危害性(Nature polluting) (N)
• GHS警示性声明: P273
• 危险公开号: 22-50
• 安全公开号: 61
• 保存温度: 2-8°C
• 德国WGK号: 3

产品详细信息

详细说明 (简体中文)

Biochem/physiol Actions
OPC-21268 is one of 2 non-peptide V1a selective antagonists, along with SR-49059. Arginine vasopressin (AVP) is a hormone that plays an important part in circulatory and water homoeostasis and is important in renal hemodynamic alterations, water retention, and cardiac remodeling in congestive heart failure (CHF). There are three AVP receptor subtypes-V1a, V1b, and V2 - all belong to the large rhodopsin-like G-protein-coupled receptor family. V(1a) antagonists improve water balance and cardiac hypertrophy in CHF and might be beneficial for the treatment of water retention and cardiac remodeling in CHF.

详细说明 (English)

Biochem/physiol Actions
OPC-21268 is one of 2 non-peptide V1a selective antagonists, along with SR-49059. Arginine vasopressin (AVP) is a hormone that plays an important part in circulatory and water homoeostasis and is important in renal hemodynamic alterations, water retention, and cardiac remodeling in congestive heart failure (CHF). There are three AVP receptor subtypes-V1a, V1b, and V2 - all belong to the large rhodopsin-like G-protein-coupled receptor family. V(1a) antagonists improve water balance and cardiac hypertrophy in CHF and might be beneficial for the treatment of water retention and cardiac remodeling in CHF.